AKBA
Akebia Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.04 EPS, $52.0M rev
Last earnings -20.3% on 2026-05-07
$1.14
▲ +9.62%$1.14▼ -69.02%
over 1Y
L $0.87EODHDH $4.01
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+9.6%
1W+4.6%
1M+10.7%
3M-14.9%
YTD-26.5%
1Y-69.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Strong Buy
Revenue grew 47.5% YoY; but unprofitable (net margin -2.3%).
Akebia Therapeutics, Inc. shows $236M in FY2025 revenue (+47.5% YoY), a -2.3% net margin, and -16.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $214M | $292M | $195M | $160M | $236M |
| Gross profit | — | — | — | — | — |
| Operating income | -$265M | -$80.8M | -$46.3M | -$50.5M | $23.5M |
| Net income | -$283M | -$94.2M | -$51.9M | -$69.4M | -$5.34M |
| Diluted EPS | -$1.70 | -$0.52 | -$0.28 | -$0.33 | -$0.02 |
| Net margin | -132.4% | -32.2% | -26.7% | -43.3% | -2.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$169M
EV / EBITDA6.7
EV / Sales0.7
EV / FCF2.5
P / FCF4.5
PEG (trailing)—
Earnings yield-1.8%
FCF yield22.2%
Quality & risk
ROIC (est.)23.0%
Free cash flow$67.7M
Total debt$48.3M
Net cash$137M
Altman Z-Score-4.61 distress
Piotroski F-Score5/8
Capital returns
Buyback yield0.1%
Dividend yield (est.)—
Shareholder yield0.1%
Shares Δ YoY+13.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗8-KPeriod ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗SCHEDULE 13GFiling2026-05-12open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEFA14AFiling2026-04-28open ↗
Frequently asked
- Is Akebia Therapeutics, Inc. (AKBA) a buy?
- AKBA currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 47.5% YoY; but unprofitable (net margin -2.3%).
- What is Akebia Therapeutics, Inc.'s quality score?
- AKBA scores 63.11764705882353/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001517022, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 7:31:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.